An Open-Label Safety and Tolerability Phase 1b Trial of CAN04 A Fully Humanized Anti-IL1RAP Monoclonal Antibody in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

An Open-Label  Safety and Tolerability Phase 1b Trial of CAN04  A Fully Humanized Anti-IL1RAP Monoclonal Antibody  in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

Brief description of study

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma.

The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab. Both CAN04 and pembrolizumab will be administered intravenously.

Adults with locally advanced (incurable) or metastatic NSCLC (adenocarcinoma, adenosquamous, or squamous), HNSCC, urothelial cancer, or malignant melanoma who experienced progression after at least 12 weeks on previous PD-1/PD-L1 inhibitor-containing regimens can be considered for participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cancer,Solid Tumors
  • Age: - 99 Years
  • Gender: All


Updated on 20 Nov 2020. Study ID: 843823

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center